Caplin has been growing steadily with latest Q3 numbers. Overall, it’s the best stock currently in the Indian market giving decent revenue growth, best-in-class GP/EBITDA margins and other efficiency metrics. I don’t think any other stock comes near to Caplin even by an inch.
With the US market coming in, focus should be on their strategy. They talked about underinsured or non-insured market. Point taken, but US market is ruthless for generics when it comes to pricing. They need to have a differentiated approach with their offerings.
With steriles & injectables as well, the same approach works.
Good point is that LATAM market will also give them a consistency while US markets with given them sudden jumps in revenue.
Subscribe To Our Free Newsletter |